HT
CRSP icon

HAP Trading’s CRISPR Therapeutics CRSP Stock Holding History

HAP Trading’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,951
Closed -$644K – 2003
2022
Q1 		$687K Sell
10,951
-4,130
-27% -$259K 0.03% 447
2021
Q4 		$1.14M Buy
+15,081
New +$1.32M 0.03% 442
2021
Q2 		– Sell
-12,583
Closed -$1.53M – 2408
2021
Q1 		$1.53M Buy
12,583
+2,029
+19% +$306K 0.08% 231
2020
Q4 		$1.62M Buy
+10,554
New +$1.25M 0.05% 311
2020
Q3 		– Sell
-12,161
Closed -$1.08M – 1626
2020
Q2 		$894K Buy
+12,161
New +$711K 0.05% 295

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

HAP Trading's CRSP Position: Q2 2022 in Review

HAP Trading sold out of CRISPR Therapeutics (CRSP) in Q2 2022, closing a stake of 10,951 shares — an estimated $644K sold.

HAP Trading first reported a position in CRSP in Q2 2020 and held it in 5 quarters. The position peaked at $1.62M in Q4 2020. 435 funds tracked by Wall St. Rank hold CRSP as of Q2 2022.

  • HAP Trading reported no remaining CRISPR Therapeutics position as of Q2 2022 after selling out during the quarter.
  • HAP Trading sold 10,951 CRISPR Therapeutics shares in Q2 2022, an estimated $644K.
  • HAP Trading first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 5 quarters.
  • HAP Trading's CRISPR Therapeutics position peaked at $1.62M in Q4 2020.
  • 435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2022.

Based on HAP Trading's 13F filing for Q2 2022, filed 12 Aug 2022.